ERBB2 and breast carcinoma: Whole genome CRISPR-Cas9 screens were carried out in two HER2-positive breast cancer cell lines (MDA-MB-361 and MDA-MB-453) treated with T-DM1 and DM1 to identify genes involved in sensitivity and resistance to these agents (Fig. 1A).